UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the Month of: November 2025
Commission
File Number: 001-40753
ICECURE
MEDICAL LTD.
(Translation
of registrant’s name into English)
7
Ha’Eshel St., PO Box 3163
Caesarea,
3079504 Israel
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒
Form 20-F ☐ Form 40-F
CONTENTS
On
November 3, 2025, IceCure Medical Ltd. (the “Company”) issued a press release titled “IceCure’s Cryoablation
System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival,”
a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K.
The
press release attached herewith as Exhibit 99.1 (excluding the second paragraph thereof) is incorporated by reference into the Company’s
Registration Statements on Form F-3 (Registration Nos. 333-258660,
333-267272 and 333-290046)
and Form S-8 (Registration Nos. 333-270982,
333-264578, 333-262620
and 333-281587), filed with
the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K
is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit
No. |
|
|
| 99.1 |
|
Press
release dated November 3, 2025 titled “IceCure’s Cryoablation System Combined with Radiation Therapy Successfully
Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival” |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
ICECURE MEDICAL LTD. |
| |
|
|
| Date: November 3, 2025 |
By: |
/s/ Eyal
Shamir |
| |
|
Name: |
Eyal Shamir |
| |
|
Title: |
Chief Executive Officer |
2
